Treating chronic hepatitis C virus (HCV) infection in certain patients.
Ledipasvir and sofosbuvir is a combination of 2 hepatitis C virus (HCV) antiviral agents.
It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.
Mechanism of action:
Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion.
Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication.
The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.